Drug Name: | Amikacin (37517-28-5) |
---|---|
PubChem ID: | 37768 |
SMILES: | C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N |
InchiKey: | LKCWBDHBTVXHDL-RMDFUYIESA-N |
Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents |
Molecular Weight (dalton) | : | 585.608 |
LogP | : | -8.4242 |
Ring Count | : | 0 |
Hydrogen Bond Acceptor Count | : | 17 |
Hydrogen Bond Donor Count | : | 13 |
Total Polar Surface Area | : | 331.94 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|---|---|---|---|
Amphotericin B (1397-89-3) | Nephrotoxicity | Antagonistic | Not fully understood | Monitoring serum aminoglycoside concentrations in children with amphotericin B nephrotoxicity |
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Aminoglycoside Toxicity | Phospholipase A (P04054) | Amikacin inhibited both phospholipase A and phospholipase C,which is possible mechanism of aminoglycoside toxicity. [ ADR Type 1 ] | Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity |
Aminoglycoside Toxicity | phospholipases C (Q9NQ66) | Amikacin inhibited both phospholipase A and phospholipase C@which is possible mechanism of aminoglycoside toxicity [ ADR Type 1 ] | Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category